<table border="1" cellpadding="0" cellspacing="0" width="90%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 1: Clinically Significant Drug Interactions with Morphine Sulfate Extended-Release Capsules
</caption>
<col width="109.6pt"></col>
<col width="403.4pt"></col>
<tbody>
<tr>
<td colspan="2" stylecode="     Toprule         Lrule          Rrule     "></td>
</tr>
<tr>
<td colspan="2" stylecode="     Toprule     ">
<paragraph>
<content stylecode="bold">Alcohol</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Concomitant use of alcohol with Morphine Sulfate Extended-Release Capsules can result in an increase of morphine plasma levels and potentially fatal overdose of morphine.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Instruct patients not to consume alcoholic beverages or use prescription or non-prescription products containing alcohol while on Morphine Sulfate Extended-Release Capsules therapy <content stylecode="italics">[see Clinical Pharmacology (<linkhtml href="#LINK_6dbaf988-f7a4-43ad-a708-683445623a25">12.3</linkhtml>)]</content>.</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Toprule     ">
<paragraph>
<content stylecode="bold">Benzodiazepines and Other Central Nervous System (CNS) Depressants</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Due to additive pharmacologic effect, the concomitant use of benzodiazepine or other CNS depressants, including alcohol, can increase the risk of hypotension, respiratory depression, profound sedation, coma, and death.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients closely for signs of respiratory depression and sedation <content stylecode="italics">[see Warnings and Precautions (<linkhtml href="#LINK_29598311-83ae-4ae8-a6d6-6cd82464a16a">5.4</linkhtml>)]</content>.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>
<content stylecode="italics">Examples:</content>
</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Benzodiazepines and other sedatives/hypnotics, anxiolytics, tranquilizers and muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol.</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Toprule     ">
<paragraph>
<content stylecode="bold">Serotonergic Drugs</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment. Discontinue Morphine Sulfate Extended-Release Capsules if serotonin syndrome is suspected.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>
<content stylecode="italics">Examples:</content>
</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT<sub>3</sub> receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Toprule     ">
<paragraph>
<content stylecode="bold">Monoamine Oxidase Inhibitors (MAOIs)</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma) <content stylecode="italics">[see Warnings and Precautions (<linkhtml href="#LINK_c8d0d2f0-6cec-4f91-8bd1-7b3217997da1">5.2</linkhtml>)]</content>.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Do not use Morphine Sulfate Extended-Release Capsules in patients taking MAOIs or within 14 days of stopping such treatment.</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Toprule     ">
<paragraph>
<content stylecode="bold">Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>May reduce the analgesic effect of Morphine Sulfate Extended-Release Capsules and/or precipitate withdrawal symptoms.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Avoid concomitant use.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>
<content stylecode="italics">Examples:</content>
</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>butorphanol, nalbuphine, pentazocine, buprenorphine</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Toprule     ">
<paragraph>
<content stylecode="bold">Muscle Relaxants</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Morphine may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Monitor patients for signs of respiratory depression that may be greater than otherwise expected and decrease the dosage of Morphine Sulfate Extended-Release Capsules and/or the muscle relaxant as necessary.</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Toprule     ">
<paragraph>
<content stylecode="bold">Cimetidine</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>The concomitant use of cimetidine can potentiate morphine effects and increase risk of hypotension, respiratory depression, profound sedation, coma, and death.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Monitor patients for signs of respiratory depression that may be greater than otherwise expected and decrease the dosage of Morphine Sulfate Extended-Release Capsules and/or cimetidine as necessary.</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Toprule     ">
<paragraph>
<content stylecode="bold">Diuretics</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Monitor patients for signs of diminished diuresis and/or effects on blood pressure and increase the dosage of the diuretic as needed.</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Toprule     ">
<paragraph>
<content stylecode="bold">Anticholinergic Drugs</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Monitor patients for signs of urinary retention or reduced gastric motility when Morphine Sulfate</paragraph>
<paragraph>Extended-Release Capsules are used concomitantly with anticholinergic drugs.</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Toprule     ">
<paragraph>
<content stylecode="bold">P-Glycoprotein (PGP) Inhibitors</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>The concomitant use of PGP-inhibitors can increase the exposure to morphine by about two-fold and can increase risk of hypotension, respiratory depression, profound sedation, coma, and death.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Monitor patients for signs of respiratory depression that may be greater than otherwise expected and decrease the dosage of Morphine Sulfate Extended-Release Capsules and/or the PGP-inhibitor as necessary.</paragraph>
</td>
</tr>
</tbody>
</table>